PT - JOURNAL ARTICLE AU - Liang, Chaoyang AU - Song, Qi AU - Zhou, Wenhao AU - Li, Na AU - Xiong, Qi AU - Pan, Chaohu AU - Zhao, Shaohong AU - Yan, Xiang AU - Zhang, Xiaoling AU - Long, Yaping AU - Guo, Juntang AU - Wang, Tao AU - Shi, Weiwei AU - Sun, Shengjie AU - Yang, Bo AU - Dong, Zhouhuan AU - Luo, Haitao AU - Li, Jie AU - Hu, Yi AU - Yang, Bo TI - Low-dose chemotherapy combined with delayed immunotherapy in the neoadjuvant treatment of non-small cell lung cancer and dynamic monitoring of the drug response in peripheral blood AID - 10.1101/2024.07.11.24310105 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.11.24310105 4099 - http://medrxiv.org/content/early/2024/07/12/2024.07.11.24310105.short 4100 - http://medrxiv.org/content/early/2024/07/12/2024.07.11.24310105.full AB - Background Despite chemo-immunotherapy has been applied to the neoadjuvant treatment of non-small cell lung cancer (NSCLC), the impacts of dosage and the order of medication on treatment efficacy and safety remain largely unexplored. We originally designed an exploratory study to investigate the efficacy and safety of reduced-dose chemotherapy combined with delayed immunotherapy as well as the dynamic changes of circulating tumor DNA (ctDNA) and T cell receptor (TCR) during the therapy.Methods Patients with clinical stage IIA to IIIA resectable NSCLC were treated with 2 cycles of reduced-dose platinum-based chemotherapy on day 1 combined with immunotherapy on day 5. The same postoperative modified adjuvant therapy regimen was administered for 2 cycles. Plasma samples at different time-points were collected and performed with T cell receptor (TCR) and circulating tumor DNA (ctDNA) sequencing.Results 38 patients received modified chemo-immunotherapy. The proportion of patients exhibiting complete response and partial response was 5.3% and 68.4%, respectively. The confirmed objective response rate was 73.7%. Radiological downstaging was achieved in 39.5%. Major pathologic response and complete pathologic response were observed in 47.4% and 31.6% of patients, respectively. Only one patient experienced grade 3 adverse event. Further analyses revealed that this modified chemo-immunotherapy led to the expansion of predominant TCR clones and reduction of tumor burden after the first cycle of chemotherapy.Conclusion The promising clinical efficacy and low side effects of modified neoadjuvant chemo-immunotherapy position it as a prospective and innovative strategy for NSCLC.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000033092Funding StatementNSFC No.81902912Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of General Hospital of the Chinese People's Liberation Army (Beijing, China) gave ethical approval (S2020-144-01)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://ngdc.cncb.ac.cn/gsa-human/